These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35366166)

  • 81. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
    Menzies AM; Long GV
    Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Optimal strategy in managing advanced melanoma.
    Uchi H
    J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
    Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 88. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
    Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Protein kinase inhibitors in melanoma.
    Eigentler TK; Meier F; Garbe C
    Expert Opin Pharmacother; 2013 Nov; 14(16):2195-201. PubMed ID: 23992377
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
    da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
    Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
    Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
    J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [mmunotherapy of cutaneous melanoma - update 2022].
    Oláh J
    Magy Onkol; 2022 Jun; 66(2):119-124. PubMed ID: 35724388
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 95. BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
    Fujimura T; Hidaka T; Kambayashi Y; Aiba S
    Expert Opin Investig Drugs; 2019 Feb; 28(2):143-148. PubMed ID: 30556435
    [TBL] [Abstract][Full Text] [Related]  

  • 96. MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma.
    Asundi J; Lacap JA; Clark S; Nannini M; Roth L; Polakis P
    Mol Cancer Ther; 2014 Jun; 13(6):1599-610. PubMed ID: 24651527
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Maximal surgical tumour load reduction in immune-checkpoint inhibitor naïve patients with melanoma brain metastases correlates with prolonged survival.
    Voglis S; Schaller V; Müller T; Gönel M; Winklhofer S; Mangana J; Dummer R; Serra C; Weller M; Regli L; Le Rhun E; Neidert MC
    Eur J Cancer; 2022 Nov; 175():158-168. PubMed ID: 36126476
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies.
    Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van Eijs MJM; de Groot JB; Hospers GAP; Kapiteijn E; de Meza M; Piersma D; Stevense-den Boer M; van der Veldt AAM; Vreugdenhil G; Wouters MWJM; Suijkerbuijk KPM; Blokx WAM
    Eur J Cancer; 2023 Jun; 186():27-37. PubMed ID: 37023588
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.
    Klobuch S; Seijkens TTP; Schumacher TN; Haanen JBAG
    Nat Rev Clin Oncol; 2024 Mar; 21(3):173-184. PubMed ID: 38191921
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
    Shin MH; Kim J; Lim SA; Kim J; Lee KM
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.